MedTrace Logo

Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration

NCT01737944 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2014-02-25

Study results available
· View outcomes & findings →

Summary

Pharmacokinetics (PK) study

Conditions

Interventions

DRUG

Methotrexate (MTX)

Vibex MTX Device

Sponsors & Collaborators

  • Antares Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Alan J Kivitz, MD;CPI · Altoona Center for Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01737944 on ClinicalTrials.gov